[Translation] A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of BRII-179 (VBI-2601) in the treatment of chronic hepatitis B virus (HBV) infection
本研究旨在评价慢性HBV感染受试者在接受现有聚乙二醇干扰素和核苷(酸)类逆转录酶抑制剂(NrtI)治疗的基础上联合BRII-179(VBI-2601)治疗的临床效果。
[Translation] This study was designed to evaluate the combination of BRII-179 (VBI-2601) on the basis of existing pegylated interferon and nucleoside (acid) reverse transcriptase inhibitor (NrtI) therapy in subjects with chronic HBV infection clinical effect.